Forthcoming Special Issue
Special Collection on Stem cells and regenerative medicine
Regenerative medicine brings promise to redefine medical treatment of acute organ injuries and degenerative human diseases. Although many breakthroughs have been reported and hailed in scientific journals over the years, the number of regenerative medicine treatments in medical use today is still limited and the efficacy is variable and transient because more comprehensive investigation is required for understanding the biology of tissue-repair and regeneration and the cellular mechanism of stem cell niche. The focus of this special issue is to capture the current advances in stem cell biology in different tissues and organs, the influence of the stem-cell niche during aging, injury and regeneration, and cell membrane repair. To be best fitting the focus of European Journal of Histochemistry, the contributions with microscopy techniques and histochemistry will be appreciated.
Potential topics include but are not limited to the following:
- Stem cells
- Cell and tissue engineering
- Regenerative medicine
- Biology of cell membrane repair
Qinan Yin, Ph.D., M.D. Research scientist, Clinical Center, National Institutes of Health, Maryland, USA.
Dr. Qinan Yin earned his Doctor of Philosophy (Ph.D.) at Tongji Medical College of Huazhong University of Science and Technology in China in 2013 and received a Doctor of Medicine (M.D.) by research at the University of Freiburg in Germany in 2014. Since September 2015, Qinan Yin is a research scientist in the Department of Transfusion Medicine, Clinical Center, NIH. Qinan Yin works to resolve the immunohematologic disorders at the molecular level through the application of advanced techniques. His research interests include stem cell surface antigens in vivo and during ex vivo expansion; immunogenetics in hematopoietic stem cell transplantation; blood group genotyping and relationship of genotype, phenotype and function of blood group proteins. His lab serves as a national reference laboratory for hospitals treating patients who develop complex or rare antibodies to variant RBC antigens, as well as supporting the patients within the NIH Clinical Center who develop, through transfusions at NIH or elsewhere, complex blood group antibodies making transfusion difficult.
E-mail: firstname.lastname@example.org; email@example.com
Xuehong Xu, Ph.D., Director of Departments of Cell Biology and Developmental Biology at Shanxi Normal University College of Life Sciences, China.
Prof. Dr. Xu services the director of Departments of Cell Biology and Developmental Biology at Shanxi Normal University College of Life Sciences, National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China. Other posts held include director of the Research Laboratory of Cell Biology, Genetics and Developmental Biology (CGDB). He graduated from Wuhan University, finished his postdoctoral trainings in Case Western Reserve University and IUPUI, and subsequently was Assistant Professor in University of Maryland School of Medicine. Dr. Xuehong Xu’s research focuses on calcium related intracellular proteins and extracellular matrix proteins involved in tissue/organ physiological development and pathological disorders. He investigates protein and gene functions during normal organogenesis as well as in hepatic, oncological and cardiovascular diseases. His researches are mainly supported by the National Natural Science Foundation of China, the Ministry of Science and Technology of China, the National Department of Education and Foreign Distinguished Scientist Program, Maryland Stem Cell Fund and American Heart Association USA.
E-mail: firstname.lastname@example.org; email@example.com
Jianjie Ma, Ph.D., Karl P. Klassen Chair in Thoracic Surgery at the Ohio State University Wexner Medical Center, Ohio, USA.
Prof. Dr. Jianjie Ma is the Karl P. Klassen Chair in Thoracic Surgery at The Ohio State University Wexner Medical Center. He is an OSU Davis Heart Lung Research Institute Investigator and serves on the advisory committee of the Center for Regenerative Medicine and Cell-Based Therapies in the College of Medicine. His research interests are in gene discovery and protein therapy in geriatric medicine, tissue repair, muscular dystrophy, cardiovascular disease, and cancer biology. He discovered MG53 as a key member of the cell membrane repair machinery. His laboratory is working to develop MG53 as a potential therapeutic agent to treat acute tissue injuries, wound healing and aging-related diseases. Dr. Ma has mentored many Ph.D. and clinician scientists who went on to become leaders in academia, medicine and pharmaceutical industries. He also serves on the editorial board of several major scientific journals and has authored or co-authored over 150 articles in peer-reviewed scientific journals.